en
Scientific article
English

Severe Vincristine-Induced Neuropathic Pain in a CYP3A5 Nonexpressor With Reduced CYP3A4/5 Activity: Case Study

Published inClinical therapeutics, vol. 38, no. 1, p. 216-220
Publication date2016
Abstract

Peripheral neuropathy is a frequent vincristine-induced adverse effect. Vincristine is a substrate of P-glycoprotein and is metabolized by the cytochrome P-450 (CYP) 3A5 and 3A4 isoforms, with CYP3A5 contributing to 75% of the intrinsic clearance of vincristine. Alterations in the function of these proteins may lead to an increase in vincristine toxicity. CYP3A5 nonexpressor status has been associated with vincristine-induced peripheral neuropathy. The severity of neuropathy has been reported to be inversely correlated to vincristine metabolite concentrations. Recently, the presence of a mutation in the CEP72 gene, which encodes for a protein involved in microtubule formation, has also been associated with vincristine-induced peripheral neuropathy. However, a clear correlation between genetic polymorphisms and vincristine toxicity has not been established.

Citation (ISO format)
BOSILKOVSKA WEISSKOPF, Marija et al. Severe Vincristine-Induced Neuropathic Pain in a CYP3A5 Nonexpressor With Reduced CYP3A4/5 Activity: Case Study. In: Clinical therapeutics, 2016, vol. 38, n° 1, p. 216–220. doi: 10.1016/j.clinthera.2015.10.017
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0149-2918
491views
2downloads

Technical informations

Creation12/11/2015 3:21:00 PM
First validation12/11/2015 3:21:00 PM
Update time03/14/2023 11:59:11 PM
Status update03/14/2023 11:59:11 PM
Last indexation05/02/2024 5:11:01 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack